Concentric Capital Strategies, LP Tg Therapeutics, Inc. Transaction History
Concentric Capital Strategies, LP
- $1.94 Billion
- Q2 2024
A detailed history of Concentric Capital Strategies, LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Concentric Capital Strategies, LP holds 42,311 shares of TGTX stock, worth $989,654. This represents 0.04% of its overall portfolio holdings.
Number of Shares
42,311
Previous 38,033
11.25%
Holding current value
$989,654
Previous $578,000
30.1%
% of portfolio
0.04%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding TGTX
# of Institutions
287Shares Held
91.8MCall Options Held
1.9MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA13.7MShares$320 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$266 Million0.0% of portfolio
-
State Street Corp Boston, MA6.7MShares$157 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.65MShares$85.3 Million6.57% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.24MShares$75.9 Million0.07% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $3.4B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...